戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ullary thyroid carcinoma not associated with multiple endocrine neoplasia.
2 rectal, ovarian and endometrial cancers, and multiple endocrine neoplasia.
3 ine tumors (NETs), with special reference to multiple endocrine neoplasia 1 (MEN1) syndrome, using a
4 or protein whose loss or inactivation causes multiple endocrine neoplasia 1 (MEN1), a hereditary auto
5 pressor protein that is encoded by the MEN1 (multiple endocrine neoplasia 1) gene and controls cell g
6 or spectrum that overlaps with the inherited multiple endocrine neoplasia-1 (MEN1) and MEN2 syndromes
7 utes of Health clarified the epidemiology of multiple endocrine neoplasia-1 syndrome.
8         These structures explain why certain multiple endocrine neoplasia 2-associated RET mutants fo
9 s, especially in von Hippel-Lindau syndrome, multiple endocrine neoplasia-2 (MEN2), and familial para
10 ding familial medullar thyroid carcinoma and multiple endocrine neoplasias 2A and 2B.
11                                           In multiple endocrine neoplasia 2B (MEN-2B) patients expres
12 ung adenocarcinoma transcript 1 (MALAT1) and multiple endocrine neoplasia-beta (MENbeta) RNAs.
13 were not associated with pituitary tumors or multiple endocrine neoplasia but were due to a heterozyg
14 al neuroendocrine tumors not associated with multiple endocrine neoplasia continue.
15 riers for highly penetrant syndromes such as multiple endocrine neoplasias, familial adenomatous poly
16 , and genetic abnormalities in patients with multiple endocrine neoplasia have been described.
17                                          The Multiple Endocrine Neoplasia I (MEN1) locus encodes the
18  and astrocytic brain tumors, paraganglioma, multiple endocrine neoplasia IIB, and neuroendocrine tum
19 in is a tumor suppressor required to prevent multiple endocrine neoplasia in humans.
20 lasia types 2A and 2B and with familial, non-multiple endocrine neoplasia medullary thyroid carcinoma
21  in the ret oncogene are the direct cause of multiple endocrine neoplasia (MEN) 2A and 2B, familial m
22                                          The multiple endocrine neoplasia (MEN) syndromes present a d
23 disease), whereas overactive RET can lead to multiple endocrine neoplasia (MEN) syndromes.
24 evelop a tumor spectrum reminiscent of human multiple endocrine neoplasia (MEN) syndromes.
25                                              Multiple endocrine neoplasia (MEN) type 1 and type 2 exh
26  most common cause of death in patients with multiple endocrine neoplasia (MEN) type 2A (MEN-2A) or t
27  carcinomas, MTCs) tumors from patients with multiple endocrine neoplasia (MEN) type 2A or 2B, relate
28  cancer may occur in isolation or as part of multiple endocrine neoplasia (MEN) type II syndromes.
29                                              Multiple endocrine neoplasia (MEN) types 1 and 2 are rar
30 lary thyroid carcinoma (MTC) associated with multiple endocrine neoplasia (MEN) types 2A and 2B and f
31 nts with familial pheochromocytomas (15 with multiple endocrine neoplasia [MEN] 2A, 4 with MEN 2B, 1
32 edullary thyroid carcinoma (MTC) and type 2A multiple endocrine neoplasia (MEN2A), mutations of cyste
33 o model of endogenous neuroendocrine tumors (multiple endocrine neoplasia [MENX]).
34 r parathyroid surgery without a diagnosis of multiple endocrine neoplasia, parathyroid cancer, or kid
35  Their presence should raise concern about a multiple endocrine neoplasia syndrome and appropriate di
36    Here, we report that rats affected by the multiple endocrine neoplasia syndrome MENX, caused by a
37 ons in the MEN1 gene are associated with the multiple endocrine neoplasia syndrome type 1 (MEN1), whi
38  years (range, <0.5-21); 13 were male, 7 had multiple endocrine neoplasia syndrome type I, 4 had unde
39 r tertiary hyperparathyroidism or those with multiple endocrine neoplasia syndrome were excluded.
40 des; medullary thyroid cancer can be part of multiple endocrine neoplasia syndrome.
41  a dominantly inherited disease and a unique multiple endocrine neoplasia syndrome.
42                           Eight patients had multiple endocrine neoplasia syndrome.
43          Activating Ret mutations also cause multiple endocrine neoplasia syndromes (MEN2A and MEN2B)
44                                          The multiple endocrine neoplasia syndromes form a distinct g
45 e reminiscent of that seen in combined human multiple endocrine neoplasia syndromes.
46 develop predictive testing for patients with multiple endocrine neoplasia syndromes.
47  gland and occurs occasionally in hereditary multiple endocrine neoplasia syndromes.
48                                     Familial multiple endocrine neoplasia type 1 (FMEN1) is an autoso
49 g in a large group of extended families with multiple endocrine neoplasia type 1 (MEN 1), with the ul
50 nts with sporadic ZES, but not in those with multiple endocrine neoplasia type 1 (MEN-1) and ZES, the
51  of heterozygosity (LOH) at the locus of the multiple endocrine neoplasia type 1 (MEN-1) gene was stu
52                                              Multiple endocrine neoplasia type 1 (MEN-1) may be assoc
53 previously identified at the locus linked to multiple endocrine neoplasia type 1 (MEN1) and as prespl
54            While mapping candidate genes for multiple endocrine neoplasia type 1 (MEN1) at 11q13, we
55                                              Multiple endocrine neoplasia type 1 (MEN1) consists of b
56                                Patients with multiple endocrine neoplasia type 1 (MEN1) develop multi
57                                              Multiple endocrine neoplasia type 1 (MEN1) is a dominant
58                                              Multiple endocrine neoplasia type 1 (MEN1) is a familial
59                                              Multiple endocrine neoplasia type 1 (MEN1) is a familial
60                                              Multiple endocrine neoplasia type 1 (MEN1) is an autosom
61                                              Multiple endocrine neoplasia type 1 (MEN1) is an autosom
62                                              Multiple endocrine neoplasia type 1 (MEN1) is an autosom
63                                              Multiple endocrine neoplasia type 1 (MEN1) is an autosom
64                                              Multiple endocrine neoplasia type 1 (MEN1) is an autosom
65                                              Multiple endocrine neoplasia type 1 (MEN1) is an inherit
66                                              Multiple endocrine neoplasia type 1 (MEN1) is an inherit
67                                              Multiple endocrine neoplasia type 1 (MEN1) is characteri
68                                              Multiple endocrine neoplasia type 1 (MEN1) is characteri
69         Primary hyperparathyroidism (HPT) in multiple endocrine neoplasia type 1 (MEN1) patients with
70 s occur both sporadically and as part of the multiple endocrine neoplasia type 1 (MEN1) syndrome.
71                    Menin, the product of the multiple endocrine neoplasia type 1 (Men1) tumor suppres
72 nscriptionally active chromatin, whereas the multiple endocrine neoplasia type 1 (MEN1) tumor suppres
73 atients with previous parathyroid surgery or multiple endocrine neoplasia type 1 (MEN1) were ineligib
74                                              Multiple endocrine neoplasia type 1 (MEN1), an autosomal
75                                              Multiple endocrine neoplasia type 1 (MEN1), an inherited
76  they are especially common in patients with multiple endocrine neoplasia type 1 (MEN1), and most stu
77 gene, mutations in which are responsible for multiple endocrine neoplasia type 1 (MEN1), encodes a 61
78                                              Multiple endocrine neoplasia type 1 (MEN1), the heritabl
79 crine tumor susceptibility syndromes such as multiple endocrine neoplasia type 1 (MEN1), von Hippel L
80 that occur sporadically and in patients with multiple endocrine neoplasia type 1 (MEN1).
81  sporadically and rarely in association with multiple endocrine neoplasia type 1 (MEN1).
82 mas can develop sporadically or as a part of multiple endocrine neoplasia type 1 (MEN1).
83  Gastrinomas and insulinomas are frequent in multiple endocrine neoplasia type 1 (MEN1).
84 s are caused by inherited syndromes, such as multiple endocrine neoplasia type 1 (MEN1).
85 duodenum occur sporadically and as a part of multiple endocrine neoplasia type 1 (MEN1).
86 ppressor gene that is mutated in humans with multiple endocrine neoplasia type 1 (MEN1).
87 t is mutated in the inherited tumor syndrome multiple endocrine neoplasia type 1 (MEN1).
88 n patients with an inherited tumor syndrome, multiple endocrine neoplasia type 1 (MEN1).
89 ith lymph node involvement and patients with multiple endocrine neoplasia type 1 did not demonstrate
90 ar, the areas of gastrinoma, insulinoma, and multiple endocrine neoplasia type 1 have received carefu
91 from pituitary adenomas in two patients with multiple endocrine neoplasia type 1 in which cells with
92                                              Multiple endocrine neoplasia type 1 is a familial cancer
93                                              Multiple endocrine neoplasia type 1 is an autosomal domi
94                                     Familial multiple endocrine neoplasia type 1 is an autosomal domi
95 ncing analysis, and deletion analysis of the multiple endocrine neoplasia type 1 locus succeeded in t
96 sm (FIHP), or as part of a syndrome, such as multiple endocrine neoplasia type 1 or hyperparathyroidi
97 e Zollinger-Ellison syndrome who do not have multiple endocrine neoplasia type 1 or metastatic diseas
98                         The genetic test for multiple endocrine neoplasia type 1 syndrome mutation wa
99  Eight patients had sporadic NETs, and 1 had multiple endocrine neoplasia type 1 syndrome.
100 ary hyperparathyroidism and one patient with multiple endocrine neoplasia type 1 syndrome.
101  the role of EUS screening for patients with multiple endocrine neoplasia type 1 syndrome.
102 nts, 123 had sporadic gastrinomas and 28 had multiple endocrine neoplasia type 1 with an imaged tumor
103 missense mutations found in individuals with multiple endocrine neoplasia type 1, and the interacting
104  in patients with ZES, especially those with multiple endocrine neoplasia type 1, and the precise ord
105 uitary neoplasias: McCune-Albright syndrome, multiple endocrine neoplasia type 1, Carney complex and,
106      Special considerations in patients with multiple endocrine neoplasia type 1, children and adoles
107 product of the MEN1 gene mutated in familial multiple endocrine neoplasia type 1, has not been define
108 ect genetic evidence that MEN1, the gene for multiple endocrine neoplasia type 1, is a tumor suppress
109 MEN1, the tumor suppressor gene disrupted in multiple endocrine neoplasia type 1.
110 , as compared with none of the patients with multiple endocrine neoplasia type 1.
111 n the diverse nature of the benign tumors in multiple endocrine neoplasia type 1.
112 sulinomas, and insulinomas in the context of multiple endocrine neoplasia type 1.
113  phaeochromocytoma (MIM No 171300) occurs in multiple endocrine neoplasia type 2 (MEN 2) (MIM No 1714
114                                              Multiple endocrine neoplasia type 2 (MEN 2) is an autoso
115                                              Multiple endocrine neoplasia type 2 (MEN 2) is an inheri
116                                              Multiple endocrine neoplasia type 2 (MEN 2) syndrome is
117 sible for the familial tumor syndrome called multiple endocrine neoplasia type 2 (MEN 2) that include
118 ase underlies the genesis and progression of multiple endocrine neoplasia type 2 (MEN 2), a dominantl
119 ery cell of the body) mutations in RET cause multiple endocrine neoplasia type 2 (MEN 2), an inherite
120 ibility are von Hippel-Lindau disease (VHL), multiple endocrine neoplasia type 2 (MEN 2), the newly d
121 to-oncogene are tumorigenic in patients with multiple endocrine neoplasia type 2 (MEN 2).
122 th the dominantly inherited cancer syndromes multiple endocrine neoplasia type 2 (MEN 2).
123 s patients with von Hippel-Lindau disease or multiple endocrine neoplasia type 2 (MEN-2), is hindered
124                                Patients with multiple endocrine neoplasia type 2 (MEN2) have mutation
125  and nonmedullary thyroid cancers related to multiple endocrine neoplasia type 2 (MEN2), Cowden syndr
126       RET germline pathogenic variants cause multiple endocrine neoplasia type 2 (MEN2), which is ass
127 logy analogous to that seen in patients with multiple endocrine neoplasia type 2 (MEN2).
128  thyroid carcinoma (MTC) and pathogenesis of multiple endocrine neoplasia type 2 (MEN2).
129  kinase lead to the familial cancer syndrome multiple endocrine neoplasia type 2 (MEN2).
130 sing a Ret-kinase-driven Drosophila model of multiple endocrine neoplasia type 2 and kinome-wide drug
131  are associated with different phenotypes of multiple endocrine neoplasia type 2 as well as sporadic
132 n-based study compiled data on patients with multiple endocrine neoplasia type 2 from 30 academic med
133 ast year addressing the surgical approach to multiple endocrine neoplasia type 2 in the pediatric pop
134 and low toxicity in Drosophila and mammalian multiple endocrine neoplasia type 2 models.
135 of medullary thyroid cancer in patients with multiple endocrine neoplasia type 2 syndrome has demonst
136  remaining 25% are hereditary and related to multiple endocrine neoplasia type 2 syndrome.
137 tential therapeutic agents for patients with multiple endocrine neoplasia type 2 tumors because both,
138                           1210 patients with multiple endocrine neoplasia type 2 were included in our
139 gical intervention in children affected with multiple endocrine neoplasia type 2 will lead to better
140 ly active oncogenic RET, were found to cause multiple endocrine neoplasia type 2, a dominant inherite
141 r, the other major neoplasia associated with multiple endocrine neoplasia type 2, phaeochromocytoma,
142                                              Multiple endocrine neoplasia type 2, von Hippel-Lindau d
143 somal dominantly inherited cancer syndromes, multiple endocrine neoplasia type 2, von Hippel-Lindau d
144 d for 84% of the patients; the other 16% had multiple endocrine neoplasia type 2, von Recklinghausen'
145                             The treatment of multiple endocrine neoplasia type 2-related phaeochromoc
146 sociated with germline RET mutations causing multiple endocrine neoplasia type 2.
147 evelopment of the inherited cancer syndrome, multiple endocrine neoplasia type 2.
148 ch encodes a receptor tyrosine kinase, cause multiple endocrine neoplasia type 2.
149 agement of phaeochromocytoma associated with multiple endocrine neoplasia type 2.
150  of oncogenic Ret receptor in a fly model of Multiple Endocrine Neoplasia Type 2.
151 or cure the endocrinopathies associated with multiple endocrine neoplasia type 2.
152 among patients with Hirschsprung disease and multiple endocrine neoplasia type 2.
153  been described as the following phenotypes: multiple endocrine neoplasia type 2A (MEN 2A) and multip
154                The majority of patients with multiple endocrine neoplasia type 2A (MEN2A) and familia
155                                              Multiple endocrine neoplasia type 2A (MEN2A) is predispo
156  the extracellular domain (ECD) of RET drive multiple endocrine neoplasia type 2A (MEN2A), a heredita
157 en identified as the aetiological factor for multiple endocrine neoplasia type 2A (MEN2A).
158 esponsible for the inherited cancer syndrome multiple endocrine neoplasia type 2A (MEN2A).
159 l as RET oncoproteins found in patients with multiple endocrine neoplasia type 2A and 2B (2A/RET and
160                                Patients with Multiple Endocrine Neoplasia type 2A should have parathy
161                                              Multiple endocrine neoplasia type 2B (MEN 2B) is caused
162 ple endocrine neoplasia type 2A (MEN 2A) and multiple endocrine neoplasia type 2B (MEN 2B) syndromes.
163  thyroid cancer (MTC) for early diagnosis of multiple endocrine neoplasia type 2B (MEN 2B).
164                                              Multiple endocrine neoplasia type 2B (MEN2B) is an autos
165                         Dominantly inherited multiple endocrine neoplasia type 2B (MEN2B) is characte
166       Adrenal-sparing surgery is feasible in multiple endocrine neoplasia type 2B and affords a good
167                                              Multiple endocrine neoplasia type 2B is a rare syndrome
168 taining the Ret mutation responsible for the multiple endocrine neoplasia type 2B syndrome (MEN 2B).
169 ases, and homologous to the codon mutated in multiple endocrine neoplasia type 2B, and many cases of
170 ding of the phenotype and natural history of multiple endocrine neoplasia type 2B, to increase awaren
171    Data are scarce on the natural history of multiple endocrine neoplasia type 2B.
172  a case of a 57-yr-old woman with history of multiple endocrine neoplasia type I (MEN I).
173                                              Multiple endocrine neoplasia type I (MEN1) is a heredita
174                                              Multiple endocrine neoplasia type I (MEN1) is an autosom
175                                              Multiple endocrine neoplasia type I (MEN1) is an inherit
176                                              Multiple endocrine neoplasia type I (MEN1) is an inherit
177                                              Multiple endocrine neoplasia type I (MEN1) is an inherit
178                                              Multiple endocrine neoplasia type I (MEN1), a hereditary
179  suppressor that is mutated in patients with multiple endocrine neoplasia type I (MEN1), an inherited
180  markers is still required for patients with multiple endocrine neoplasia type I because the responsi
181 or in a patient with a known mutation in the multiple endocrine neoplasia type I gene.
182 hese include menin, which is responsible for multiple endocrine neoplasia type I, and the hybrid gene
183 milial predisposition to pheochromocytoma in multiple endocrine neoplasia type II, and mutations in t
184 beta), T-type calcium channel (CACNA1G), and multiple endocrine neoplasia type-1 (MEN1) genes, and of
185 have shown that the gene responsible for the multiple endocrine neoplasia type-1 (MEN1) syndrome loca
186  targets of tumorigenesis in the syndrome of multiple endocrine neoplasia type-1 (MEN1).
187                                              Multiple endocrine neoplasia, type 1 (MEN I), is an auto
188 S were studied prospectively, with 39 having multiple endocrine neoplasia, type 1 (MEN-1) (high incre
189                       BACKGROUND & AIMS: The multiple endocrine neoplasia, type 1 (MEN1) locus encode
190 d with cystic fibrosis, hemochromatosis, and multiple endocrine neoplasia, type 2, respectively.
191                                              Multiple endocrine neoplasia, type I (MEN1) is an inheri
192 even of 61 (11%) patients had a diagnosis of multiple endocrine neoplasia-type 1 (MEN-1).
193                                              Multiple endocrine neoplasia-type 1 (MEN1) is an autosom
194 -Ellison syndrome or nonfunctional PETs with multiple endocrine neoplasia-type 1.
195 gical cure rate in patients with and without Multiple Endocrine Neoplasia-type1 (MEN1), the biologica
196                                 They include multiple endocrine neoplasia types 1 and 2, von Hippel L
197 de the dominantly inherited cancer syndromes multiple endocrine neoplasia types 2A and 2B (MEN 2A and
198  Experience with management of patients with multiple endocrine neoplasia types 2A and 2B and with fa
199 , breast cancer, acute myelogenous leukemia, multiple endocrine neoplasia types 2A and 2B, and famili
200 gene have been demonstrated in patients with multiple endocrine neoplasia types IIA, IIB, and familia
201                                Patients with multiple endocrine neoplasia were excluded.

 
Page Top